Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Iododoxorubicin may dissolve protein deposits and be an effective treatment for primary
systemic amyloidosis. Phase I trial to determine the effectiveness of iododoxorubicin in
treating patients who have primary systemic amyloidosis